Facing the challenges of high-cost medicines : multinational comparison of the pricing and reimbursement decision-making processes for the new Hepatitis C treatments
The therapeutic landscape of Hepatitis C virus (HCV) infection has changed dramatically since 2013 when “life-saving” direct-acting antivirals (HCV-DAAs) entered the global market. Although behind such a huge biomedical stride, their high prices have been criticised globally as a barrier to patient...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
London School of Hygiene and Tropical Medicine (University of London)
2018
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.755902 |